Geopolitics and Financial Profitability, the Big Pharmaceutical Dispute
Abstract
Faced with the necessary measures taken by governments to stop the spread of the virus, fiscal policies were established to face the fall caused by the closure of the global economy. Just at that moment the ring opened for the big pharmaceutical companies to achieve a vaccine in a short time that would generate great profits for their shareholders. Unlocking the economy to prevent the losses of non-financial corporations from continuing to decline was a priority given the fracture of global production chains; an imminent and necessary return of the workforce to reestablish the production process and guarantee the profitability of the institutional investors who dominate the financial circuits in the global economy. The dispute to create a vaccine based on the profitability of the shareholders of the pharmaceutical finance capital lies in a merchandise whose use value psychologically provides the plaintiffs, return to the 'normality' prior 2020.The vaccine is a commodity that will position the shareholders of pharmaceutical industry companies in a profit economy where, beyond stopping the pandemic and contagion and deaths, the important thing has been to restore the economic order regardless of the informality of the employment, nor the decrease in the income of wage earners, the failure of small and medium-sized companies, fractured value chains that have maintained a dual economy for several decades. Inequalities within countries and between nations have come to light not only because of the questioning of who has the technology to produce vaccines, but also of the governments that had the money to purchase them and that are controlling production. Beyond freeing up knowledge and technology to produce vaccines, the evidence is the geopolitical role that the pandemic is playing as it crosses countries leaving them in disparity with others.